At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIB ProShares Ultra Nasdaq Biotechnology
Not Yet Opened 10-19 16:00:00 EDT
107.09
+1.98
+1.89%
盘后107.29
+0.20+0.19%
16:04 EDT
High109.00Low106.48Vol2.30K
Open108.50D1 Closing105.10Amplitude2.40%
Mkt Cap89.95MTradable Cap89.95MTotal Shares840.00K
T/O246.60KT/O Rate0.27%Tradable Shares840.00K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

PRESS Digest -Wall Street Journal - October 20
Reuters  ·  13:03
PRESS Digest -Wall Street Journal - October 20
Gilead Sciences Inc. Stock Underperforms Monday When Compared to Competitors
Dow Jones  ·  04:34
Gilead Sciences Inc. Stock Underperforms Monday When Compared to Competitors
Moderna Inc. Stock Advances 4.1%, Outperforms Peers
Dow Jones  ·  04:33
Moderna Inc. Stock Advances 4.1%, Outperforms Peers
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
TIPRANKS  ·  10-19 23:19
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
Gilead to present new data across HIV, antiviral research at IDWeek
TIPRANKS  ·  10-19 20:20
Gilead to present new data across HIV, antiviral research at IDWeek
Mattel Names Peter Griffith CFO and Board Director
Reuters  ·  10-19 20:06
Mattel Names Peter Griffith CFO and Board Director
Abivax Shares Fall After Rival Drug Data, Trader Says
Reuters  ·  10-19 19:47
Abivax Shares Fall After Rival Drug Data, Trader Says
Abivax Shares Fall, Last Down 6.8% After Rival Gilead Pill Succeeds in Mid Stage Bowel Disease Trial - Trader
THOMSON REUTERS  ·  10-19 19:01
Abivax Shares Fall, Last Down 6.8% After Rival Gilead Pill Succeeds in Mid Stage Bowel Disease Trial - Trader
Gilead - Emvistegrast 200 Mg Demonstrated Significant Differences Across Multiple Secondary Measures of Disease Activity Based on Nominal P-Values
THOMSON REUTERS  ·  10-19 18:01
Gilead - Emvistegrast 200 Mg Demonstrated Significant Differences Across Multiple Secondary Measures of Disease Activity Based on Nominal P-Values
Gilead - Emvistegrast 200 Mg Showed Generally Well-Tolerated Safety Profile
THOMSON REUTERS  ·  10-19 18:01
Gilead - Emvistegrast 200 Mg Showed Generally Well-Tolerated Safety Profile
Gilead: Emvistegrast 200Mg Achieves 66% Clinical Response vs 37% Placebo at Week 12 in Ulcerative Colitis
THOMSON REUTERS  ·  10-19 18:01
Gilead: Emvistegrast 200Mg Achieves 66% Clinical Response vs 37% Placebo at Week 12 in Ulcerative Colitis
Gilead - Emvistegrast 200 Mg Met the Primary Endpoint in Phase 2 Swift Dose-Ranging Study
THOMSON REUTERS  ·  10-19 18:01
Gilead - Emvistegrast 200 Mg Met the Primary Endpoint in Phase 2 Swift Dose-Ranging Study
Gilead: Plans to Initiate Phase 3 Emvistegrast Monotherapy Study in 2027
THOMSON REUTERS  ·  10-19 18:01
Gilead: Plans to Initiate Phase 3 Emvistegrast Monotherapy Study in 2027
Gilead's Emvistegrast Meets Primary Endpoint in Phase 2 Ulcerative Colitis Trial
Reuters  ·  10-19 16:40
Gilead's Emvistegrast Meets Primary Endpoint in Phase 2 Ulcerative Colitis Trial
Gilead Sciences (GILD) Could Be 22% Overvalued On Fresh Drug Approvals
Simply Wall St.  ·  10-19 14:30
Gilead Sciences (GILD) Could Be 22% Overvalued On Fresh Drug Approvals
Moderna Inc. Stock Slides 7.8%, Underperforms Peers
Dow Jones  ·  10-17
Moderna Inc. Stock Slides 7.8%, Underperforms Peers
Vortex Energy Extends €100,000 Digital Marketing Campaign to Boost Investor Visibility
TIPRANKS  ·  10-16
Vortex Energy Extends €100,000 Digital Marketing Campaign to Boost Investor Visibility
Gilead Sciences to Report Third-Quarter Financial Results
Reuters  ·  10-16
Gilead Sciences to Report Third-Quarter Financial Results
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
THOMSON REUTERS  ·  10-16
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Healthcare Stocks are on a Tear. Gilead and AbbVie are Heading for Record Highs.
Dow Jones  ·  10-16
Healthcare Stocks are on a Tear. Gilead and AbbVie are Heading for Record Highs.
No data available

Introduction

Company Name.
ProShares Ultra Nasdaq Biotechnology
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Issue price:
--